Clik here to view.
Lilly inks radiopharma deal with Radionetics, with rights to buy the biotech
Eli Lilly is further delving into the radiopharmaceutical field with a $140 million upfront deal with Radionetics Oncology. The strategic pact with the San Diego biotech could turn into a $1 billion...
View ArticleTracon to seek ‘strategic’ options; Ovid to lay off 17 workers
Plus, news about Merck, Orion, Tonix, Freeflow and Y-mAbs Therapeutics: Tracon Pharmaceuticals seeks ‘strategic alternatives’ after PD-L1 fails Ph2 trial: In an 82-person sarcoma study, only four...
View ArticleUniQure sells Massachusetts manufacturing site to Genezen as it continues to...
UniQure is selling its only US manufacturing site to viral vector CDMO Genezen for $25 million, as the gene therapy biotech continues to trim operations. The Lexington, MA, site makes uniQure’s...
View ArticleCorrected: Boehringer Ingelheim, Gubra put a second candidate into the...
Boehringer Ingelheim is beginning an early-stage trial for a triple agonist candidate for obesity that it’s developing with Danish biotech Gubra. The drug, dubbed BI 3034701, will be tested in a...
View ArticleFDA says chemotherapy cisplatin is no longer in short supply
According to the FDA and a triumphant tweet from FDA Commissioner Robert Califf, the shortage of the cancer drug cisplatin that began in February of last year has been resolved. The supply issues for...
View ArticleTakeda to lay off more employees in Massachusetts
Takeda plans to let go another 220 staffers in Massachusetts, where it was the largest biopharma in 2023 with 6,290 workers. The workforce reduction impacts 189 employees in Cambridge and 31 in...
View ArticleCassava says two senior employees included in federal probes
Following years of accusations of scientific malfeasance, Alzheimer’s drug developer Cassava Sciences disclosed Monday that two of its senior employees are being investigated by the US Securities and...
View ArticleSeeking 'financial flexibility,' Esperion sells European royalty on...
Esperion has made another deal with a financial backer for an immediate cash haul in return for future revenue. Esperion received $304.7 million from the investor OMERS Life Sciences, the biotech...
View ArticleFTC investigates Teva over patents, doubling down on 'bogus' Orange Book...
The Federal Trade Commission has turned up the pressure in its patent probe, officially launching a civil investigation into a group of Teva’s drug patents that the agency claims are improperly listed...
View ArticleCartesian clears an autoimmune CAR-T trial, starts another Phase 2 and raises...
Cartesian Therapeutics, an mRNA cell therapy biotech, said its lead investigational medicine helped patients with an autoimmune condition that has caught the attention of many biopharmas in recent...
View ArticleSamsung Bio pulls in $1.06B manufacturing deal with unnamed US pharma company
Samsung Biologics has signed a manufacturing contract worth 1.46 trillion won ($1.06 billion) with an unnamed “large” US pharmaceutical company, making this at least the fourth major contract the...
View Article#EASD24: Weight loss readouts from Novo Nordisk, Boehringer Ingelheim,...
Companies large and small are set to present data on their next-generation weight loss drug candidates at the European Association for the Study of Diabetes annual meeting in Madrid, Spain. The...
View ArticleJ&J and Legend say Carvykti improved survival in earlier-line multiple myeloma
In a late-stage study, Johnson & Johnson and Legend Biotech’s CAR-T therapy Carvykti improved survival in multiple myeloma patients who had received one to three prior lines of therapy compared to...
View ArticleCheckpoint Therapeutics refiles PD-L1 drug cosibelimab after FDA rejection
Checkpoint Therapeutics is taking a second shot at approval for its anti-PD-L1 candidate after the FDA rejected its first submission around seven months ago due to issues at a third-party manufacturer....
View ArticleFollowing a pivotal trial fail and layoffs, Ovid finds itself in a familiar spot
Last week, Ovid Therapeutics disclosed layoff plans in an SEC filing following a Phase 3 flop for its Takeda-partnered epilepsy program. The news sent its stock price $OVID down 70%. Ovid has been here...
View ArticleYuhan, Ubix ink licensing deal; Xenpozyme's royalty deal
Plus, news about Ipsen, Exelixis, Innovent, Codexis, Crosswalk Therapeutics and J&J: Yuhan licenses prostate cancer drug: The biotech will pay Seoul-based Ubix Therapeutics $3.6 million upfront and...
View ArticleClik here to view.
Moderna wins $176M BARDA award to finance bird flu work
Moderna received a significant boost from the federal government, snagging a $176 million contract to help advance a bird flu vaccine. The award, which was granted by the Biomedical Advanced Research...
View ArticleAs confidence falls, biopharma companies take precautions with Chinese...
Geopolitical tensions and threats of decoupling have led to a steep decline in American companies’ confidence in working with Chinese partners, although few have taken steps to end relationships,...
View Article'Optimizing R&D structure is also on the horizon, without exception,' new...
Sumitomo Pharma CEO Toru Kimura says that he sees the need to streamline the company’s business and product lineup, and is considering steps including job cuts. He’s also looking at how to optimize the...
View ArticleEli Lilly wins long-awaited approval for Alzheimer’s drug
After decades of trying to develop a treatment for Alzheimer’s disease, Eli Lilly has finally won FDA approval for its drug donanemab, which will be marketed as Kisunla. An approval was originally...
View Article